Latest News
Apricus Biosciences' partner to be the first to launch Vitaros for treating erectile dysfunction in Europe
17 April 2014 - Pharmaceutical company Apricus Biosciences (NasdaqCM:APRI) disclosed on Wednesday the first shipment of its novel topical on-demand treatment for erectile dysfunction (ED) Vitaros in the UK.

The UK launch is being initiated by the company's UK partner, Takeda Pharmaceuticals International GmbH.

According to IMS Health, the erectile dysfunction market in the UK was worth approximately USD225m in 2013, the largest ED market in Europe. The product received regulatory approval in Europe in June of 2013 and in August of 2013, Apricus received the national phase approval to have the product marketed in the UK.

In conjunction with manufacturing commercial products, Apricus will provide clinical support for its partners' pre-commercialisation activities in an effort to facilitate a consistent launch of Vitaros throughout 2014.

Login
Username:

Password: